CA2256449A1 - Peptides immunoreactifs par rapport aux apl, leurs conjugues et procedes de traitement des pathologies dependantes de l'anticorps apl - Google Patents

Peptides immunoreactifs par rapport aux apl, leurs conjugues et procedes de traitement des pathologies dependantes de l'anticorps apl Download PDF

Info

Publication number
CA2256449A1
CA2256449A1 CA002256449A CA2256449A CA2256449A1 CA 2256449 A1 CA2256449 A1 CA 2256449A1 CA 002256449 A CA002256449 A CA 002256449A CA 2256449 A CA2256449 A CA 2256449A CA 2256449 A1 CA2256449 A1 CA 2256449A1
Authority
CA
Canada
Prior art keywords
apl
phage
antibody
peptide
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002256449A
Other languages
English (en)
Inventor
Edward Jess Victoria
David Matthew Marquis
David S. Jones
Lin Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/660,092 external-priority patent/US6207160B1/en
Application filed by Individual filed Critical Individual
Publication of CA2256449A1 publication Critical patent/CA2256449A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)

Abstract

Analogues de l'anticorps antiphospholipide (aPL) qui (a) se lient spécifiquement aux lymphocytes B auxquels un épitope d'aPL se lie. Des analogues optimisés qui sont exempts du ou des épitopes de lymphocytes T sont utiles comme conjugués pour traiter des maladies dépendantes de l'anticorps aPL. Des conjugués comprenant des analogues d'aPL et des molécules à plate-forme de valence non immunogènes sont décrits, ainsi que de nouvelles molécules à plate-forme de valence non immunogènes et des séquences de liaison, des procédés de préparation et d'identification desdits analogues, de procédés de traitement au moyen desdits analogues, des procédés et des compositions destinés à la préparation de conjugués desdits analogues, et des dosages immunologiques et diagnostiques pour les anticorps aPL.
CA002256449A 1996-06-06 1997-06-06 Peptides immunoreactifs par rapport aux apl, leurs conjugues et procedes de traitement des pathologies dependantes de l'anticorps apl Abandoned CA2256449A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/660,092 US6207160B1 (en) 1995-06-07 1996-06-06 aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
US76050896A 1996-12-05 1996-12-05
US08/760,508 1996-12-05
US08/660,092 1996-12-05
PCT/US1997/010075 WO1997046251A1 (fr) 1996-06-06 1997-06-06 PEPTIDES IMMUNOREACTIFS PAR RAPPORT AUX aPL, LEURS CONJUGUES ET PROCEDES DE TRAITEMENT DES PATHOLOGIES DEPENDANTES DE L'ANTICORPS aPL

Publications (1)

Publication Number Publication Date
CA2256449A1 true CA2256449A1 (fr) 1997-12-11

Family

ID=27097975

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002256449A Abandoned CA2256449A1 (fr) 1996-06-06 1997-06-06 Peptides immunoreactifs par rapport aux apl, leurs conjugues et procedes de traitement des pathologies dependantes de l'anticorps apl

Country Status (7)

Country Link
EP (1) EP0954531A1 (fr)
JP (1) JP2000512981A (fr)
KR (1) KR20000016414A (fr)
AU (1) AU734638B2 (fr)
CA (1) CA2256449A1 (fr)
NO (1) NO985636L (fr)
WO (1) WO1997046251A1 (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009690A2 (fr) * 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6858210B1 (en) * 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
WO2000006717A2 (fr) 1998-07-27 2000-02-10 Genentech, Inc. Efficacite de transformation amelioree de l'expression a la surface des phages par modification d'une proteine de coque
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
GB9919452D0 (en) * 1999-08-17 1999-10-20 Osteometer Biotech As Specific autoimmune reactions against isomerised/optically inverted epitopes:application for diagnosis of autoimmune diseases
WO2001032858A1 (fr) * 1999-11-05 2001-05-10 Novozymes A/S Procede de criblage a haut debit (hts)
EP1233791A2 (fr) 1999-11-28 2002-08-28 La Jolla Pharmaceutical Company Procedes de traitement de lupus sur la base de l'affinite aux anticorps et procedes de criblage et compositions associees
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002002641A1 (fr) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
EP1674477B1 (fr) 2000-08-18 2009-12-09 Dyax Corp. Polypeptides de liaison pour la protéine stimulatrice des lymphocytes B (BLyS)
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100628425B1 (ko) 2001-06-20 2006-09-28 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
JP4598389B2 (ja) 2001-06-21 2010-12-15 ダイナバックス テクノロジーズ コーポレイション キメラ免疫調節化合物とその使用方法
AU2002330015B2 (en) 2001-09-18 2008-02-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2471431A1 (fr) 2002-01-02 2003-07-17 Genentech, Inc. Compositions et methodes de diagnostic et de traitement d'une tumeur
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN100471486C (zh) 2002-08-12 2009-03-25 戴纳伐克斯技术股份有限公司 免疫调节组合物,其制备方法和使用方法
MX341074B (es) 2003-07-08 2016-08-05 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
SI2295073T1 (sl) 2003-11-17 2014-07-31 Genentech, Inc. Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
PL1794174T3 (pl) 2004-09-01 2012-11-30 Dynavax Tech Corp Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
JP2008535796A (ja) 2005-03-10 2008-09-04 ジェネンテック・インコーポレーテッド 脈管の完全性を調節するための方法及び組成物
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
CA2647277A1 (fr) 2006-04-05 2007-11-08 Genentech, Inc. Methode d'utilisation du boc/cdo pour moduler l'emission des signaux du hedgehog
EP2057465A4 (fr) 2006-08-09 2010-04-21 Homestead Clinical Corp Protéines spécifiques d'organes et procédés d'utilisation
US20080096208A1 (en) 2006-09-06 2008-04-24 Connors Richard W Biomarkers for assessing response to c-met treatment
JPWO2008032833A1 (ja) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Ａｄｃｃ活性を増強させた抗体及びその製造方法
AU2008218199B2 (en) 2007-02-22 2013-10-31 Genentech, Inc. Methods for detecting inflammatory bowel disease
AU2008317261B2 (en) 2007-10-26 2015-04-09 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
EP2304439A4 (fr) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc Anticorps anti-phospho-akt
WO2009154025A1 (fr) 2008-06-20 2009-12-23 国立大学法人岡山大学 ANTICORPS CONTRE UN COMPLEXE LDL/β2GPI OXYDÉ ET SON UTILISATION
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
ES2564207T3 (es) 2009-10-22 2016-03-18 F. Hoffmann-La Roche Ag Métodos y composiciones para modular la activación con hepsina de la proteína estimuladora de macrófagos
EP3002297B1 (fr) 2009-11-30 2020-04-08 F. Hoffmann-La Roche AG Anticorps pour le traitement et la diagnose du tumeurs exprimant slc34a2 ( tat211 )
AR080243A1 (es) 2010-02-23 2012-03-21 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
KR20130079384A (ko) 2010-05-03 2013-07-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US8940310B2 (en) 2010-06-16 2015-01-27 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
CA2822442C (fr) * 2010-12-22 2021-03-16 The Salk Institute For Biological Studies Peptides cycliques antagonistes de la corticoliberine
WO2012129347A1 (fr) 2011-03-21 2012-09-27 Biodesy, Llc Classification d'inhibiteurs de kinase à l'aide de techniques optiques non linéaires
EP2756300A1 (fr) 2011-09-15 2014-07-23 F.Hoffmann-La Roche Ag Procédés de promotion de la différenciation
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
BR112014017626A2 (pt) 2012-01-18 2018-05-22 Genentech Inc métodos para tratar uma doença ou disfunção, métodos de identificação de um indivíduo, método para prever se um indivíduo com uma doença ou disfunção tem mais ou menos probabilidade para desenvolver toxicidade ao tratamento, método para determinar se um indivíduo com uma doença ou disfunção deve continuar ou suspender o tratamento que compreende um modulador de fgf19, método de otimização de eficácia terapêutica e método de ensaio
MX366804B (es) 2012-02-11 2019-07-25 Genentech Inc Translocaciones de la r-espondina y sus metodos de uso.
JP2015511598A (ja) 2012-03-16 2015-04-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐａｋ１阻害剤を用いて黒色腫を治療する方法
MX2014010943A (es) 2012-03-16 2014-11-26 Genentech Inc Proteinas estabilizadas conformacionalmente de ingenieria.
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
GB2517857A (en) 2012-04-25 2015-03-04 Biodesy Inc Methods for detecting allosteric modulators of proteins
WO2013170191A1 (fr) 2012-05-11 2013-11-14 Genentech, Inc. Procédés d'utilisation d'antagonistes de biosynthèse de nicotinamide adénine dinucléotide à partir de nicotinamide
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
SG10201701380TA (en) 2013-03-15 2017-04-27 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2015116902A1 (fr) 2014-01-31 2015-08-06 Genentech, Inc. Récepteurs couplés aux protéines g dans la signalisation hedgehog
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
JP6655074B2 (ja) 2014-06-20 2020-02-26 ジェネンテック， インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
WO2016106286A1 (fr) 2014-12-23 2016-06-30 Biodesy, Inc. Fixation de protéines à des interfaces destinées à être utilisées en détection optique non linéaire
AU2016252773B2 (en) 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
WO2018049275A1 (fr) 2016-09-09 2018-03-15 Genentech, Inc. Inhibiteurs peptidiques sélectifs de frizzled
WO2018152496A1 (fr) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions et méthodes de diagnostic et de traitement de l'infection par le virus zika
US11236151B2 (en) 2017-04-25 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
WO2019018629A1 (fr) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Anticorps et procédés de diagnostic et de traitement d'infection par le virus de l'hépatite b
CA3134016A1 (fr) 2019-05-09 2020-11-12 Genentech, Inc. Procedes de preparation d'anticorps
CN112480209B (zh) * 2020-11-16 2022-03-04 昆明学院 一种抗皮肤光损伤保护活性多肽rl-pl9及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU640699B2 (en) * 1989-10-19 1993-09-02 Yamasa Shoyu Kabushiki Kaisha Carrier for binding antiphospholipid antibody, immunoassay using the same, and kit therefor
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
CA2058769C (fr) * 1990-04-06 1999-03-02 Steven Anthony Krilis Methodes pour le dosage des phospholipides et de leurs anticorps
WO1991015722A1 (fr) * 1990-04-10 1991-10-17 Masur, Walter Processus de fonctionnement d'une thermopompe a compression et thermopompe a compression
ATE359830T1 (de) * 1993-09-08 2007-05-15 Jolla Pharma Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies

Also Published As

Publication number Publication date
NO985636D0 (no) 1998-12-03
EP0954531A1 (fr) 1999-11-10
EP0954531A4 (fr) 1999-08-31
AU734638B2 (en) 2001-06-21
NO985636L (no) 1999-02-08
WO1997046251A1 (fr) 1997-12-11
KR20000016414A (ko) 2000-03-25
AU3640497A (en) 1998-01-05
JP2000512981A (ja) 2000-10-03

Similar Documents

Publication Publication Date Title
CA2256449A1 (fr) Peptides immunoreactifs par rapport aux apl, leurs conjugues et procedes de traitement des pathologies dependantes de l'anticorps apl
US6207160B1 (en) aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
WO1996040197A9 (fr) PEPTIDES A IMMUNOREACTION aPL, LEURS CONJUGUES, ET METHODES DE TRAITEMENT DES PATHOLOGIES INDUITES PAR LES ANTICORPS aPL
WO1997046251A9 (fr) PEPTIDES IMMUNOREACTIFS PAR RAPPORT AUX aPL, LEURS CONJUGUES ET PROCEDES DE TRAITEMENT DES PATHOLOGIES DEPENDANTES DE L'ANTICORPS aPL
AU772851B2 (en) Therapeutic and diagnostic domain 1 beta2GPI polypeptides and methods of using same
Valadon et al. Peptide libraries define the fine specificity of anti-polysaccharide antibodies toCryptococcus neoformans
JP6254527B2 (ja) 構造化ポリペプチドの特異性のモジュレーション
US20050214852A1 (en) Peptides for the treatment and diagnosis of systemic lupus erythematosus
CN103263664A (zh) 预防和治疗阿尔茨海默病的方法
US6410775B1 (en) APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
JP2011016763A (ja) 疎水性ペプチドに対する抗体の製造方法
Cook et al. Mimotopes identified by phage display for the monoclonal antibody CII-C1 to type II collagen
US7569541B2 (en) Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines
WO2022025264A1 (fr) Séquence d'acides aminés dérivée de sars-cov-2 et son utilisation
US20040176283A1 (en) Methods and compositions for the design of synthetic vaccines
US20030118604A1 (en) Antigenic structural peptide, antigenic and immunogenic compounds, and uses for detecting, preventing and treating an HCV infection
US7592421B1 (en) HLA class II peptide mimics
AU2004201699A1 (en) Therapeutic and diagnostic domain 1 Beta2GPI polypeptides and methods of using same
Tuteja 7 Mimotopes: An Overview
CN1225015A (zh) aPL免疫反应性肽、其缀合物以及aPL抗体介导的疾病的治疗方法
MXPA00012040A (en) THERAPEUTIC AND DIAGNOSTIC DOMAIN 1&bgr;2
Khudyakov Artificial
Zhi-Jian Yao et al. Identifying antigenic region of hepatitis B surface antigen by patient's serum with random peptide library

Legal Events

Date Code Title Description
FZDE Dead